|
IL304040B2
(en)
|
2016-07-07 |
2024-09-01 |
Hughes Howard Med Inst |
Modified ligand-gated ion channels and methods of use
|
|
US12459965B2
(en)
|
2017-10-09 |
2025-11-04 |
Compass Pathfinder Limited |
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
SG11202004246YA
(en)
|
2017-11-10 |
2020-06-29 |
Hughes Howard Med Inst |
Modified ligand-gated ion channels and methods of use
|
|
CA3132731A1
(en)
*
|
2019-03-07 |
2020-09-10 |
University Of Padova |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
US12377112B2
(en)
|
2019-04-17 |
2025-08-05 |
Compass Pathfinder Limited |
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
|
|
EP4003395A4
(en)
*
|
2019-07-23 |
2023-07-19 |
Caamtech, Inc. |
COMPOSITIONS WITH TOAD SECRETION COMPOUNDS
|
|
CA3152752A1
(en)
|
2019-10-01 |
2021-04-08 |
Thomas Henley |
Genetic engineering of fungi to modulate tryptamine expression
|
|
AU2020358869A1
(en)
|
2019-10-03 |
2022-04-14 |
Pike Therapeutics Usa, Inc. |
Transdermal delivery of dronabinol
|
|
US12409131B2
(en)
|
2019-10-03 |
2025-09-09 |
Pike Therapeutics Usa, Inc. |
Transdermal delivery of dronabinol
|
|
EP4041209A4
(en)
|
2019-10-11 |
2024-01-24 |
Pike Therapeutics, Inc. |
TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
|
|
US12016829B2
(en)
|
2019-10-11 |
2024-06-25 |
Pike Therapeutics Inc. |
Pharmaceutical composition and method for treating seizure disorders
|
|
CA3155181A1
(en)
|
2019-10-14 |
2021-04-22 |
Pike Therapeutics, Inc., 1219014 B.C. Ltd. |
Transdermal delivery of cannabidiol
|
|
US12121617B2
(en)
|
2019-10-14 |
2024-10-22 |
Pike Therapeutics Inc. |
Transdermal delivery of cannabidiol
|
|
US12268699B2
(en)
|
2019-10-14 |
2025-04-08 |
Pike Therapeutics Inc. |
Transdermal delivery of tetrahydrocannabinol
|
|
WO2021072530A1
(en)
*
|
2019-10-15 |
2021-04-22 |
Tassili Life Sciences, Corp. |
Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
|
|
CA3160793A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Neonmind Biosciences Inc. |
Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
|
|
US20210220336A1
(en)
*
|
2020-01-22 |
2021-07-22 |
Clexio Biosciences Ltd. |
Topical detomidine formulations
|
|
KR20220137081A
(ko)
|
2020-02-04 |
2022-10-11 |
마인드셋 파마 인크. |
Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
|
|
BR112022015379A2
(pt)
|
2020-02-04 |
2022-09-27 |
Mindset Pharma Inc |
Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
|
|
EP4135713A4
(en)
*
|
2020-04-17 |
2024-04-17 |
Revive Therapeutics Ltd. |
Use of psilocybin in the treatment of neurological brain injury and migraines
|
|
WO2021225796A1
(en)
|
2020-05-05 |
2021-11-11 |
Universitätsspital Basel |
Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
|
|
WO2021226416A1
(en)
|
2020-05-08 |
2021-11-11 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
WO2021243460A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Neonmind Biosciences Inc. |
Method for weight loss with therapy
|
|
WO2022023812A1
(en)
*
|
2020-07-29 |
2022-02-03 |
Diamond Therapeutics Inc. |
Extended release 5-ht receptor agonists for neurological conditions
|
|
US20220062310A1
(en)
*
|
2020-09-03 |
2022-03-03 |
Yale University |
Psilocybin in patients with obsessive-compulsive disorder
|
|
WO2022072808A1
(en)
*
|
2020-10-01 |
2022-04-07 |
Mydecine Innovations Group Inc. |
Novel psychedelic compositions, delivery systems and therapeutic uses thereof
|
|
CA3197488A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Goodcap Pharmaceuticals Ltd. |
Compositions for reducing inflammation to improve or maintain mental or physical health
|
|
US12029718B2
(en)
|
2021-11-09 |
2024-07-09 |
Cct Sciences, Llc |
Process for production of essentially pure delta-9-tetrahydrocannabinol
|
|
US20230398234A1
(en)
*
|
2020-10-28 |
2023-12-14 |
Mydecine Innovations Group Inc. |
Novel fungal compoind formulations and their therapeutic methods of use
|
|
WO2022115798A2
(en)
*
|
2020-11-30 |
2022-06-02 |
Wesana Health Inc. |
Compositions and methods for treating migraine
|
|
WO2022115796A1
(en)
*
|
2020-11-30 |
2022-06-02 |
Wesana Health Inc. |
Compositions and methods for treating neurological conditions
|
|
KR20230109765A
(ko)
|
2020-12-09 |
2023-07-20 |
캄테크, 인크. |
다이알킬 트립타민 및 이의 치료적 용도
|
|
CA3113240C
(en)
|
2020-12-28 |
2023-09-05 |
Psilo Scientific Ltd. |
Transmucosal psychoactive alkaloid composition and preparation thereof
|
|
US12534441B2
(en)
|
2021-01-15 |
2026-01-27 |
Beckley Psytech Limited |
Tryptamine analogues
|
|
EP4155306A1
(en)
|
2021-01-15 |
2023-03-29 |
Beckley Psytech Limited |
Neuroactive ergoline analogue
|
|
US20220265601A1
(en)
*
|
2021-02-10 |
2022-08-25 |
David Alan Heldreth, JR. |
Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
|
|
US11312684B1
(en)
|
2021-02-10 |
2022-04-26 |
Eleusis Therapeutics Us, Inc. |
Pharmaceutically acceptable salts of psilocin and uses thereof
|
|
US20220273628A1
(en)
*
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
US20220370413A1
(en)
*
|
2021-03-06 |
2022-11-24 |
Mind Medicine, Inc. |
Formulations of psilocin that have enhanced stability
|
|
EP4304603A4
(en)
*
|
2021-03-08 |
2025-01-22 |
Diamond Therapeutics Inc. |
5-ht receptor agonist titration
|
|
WO2022204323A1
(en)
*
|
2021-03-24 |
2022-09-29 |
The Trustees Of Columbia University In The City Of New York |
Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders
|
|
TW202304466A
(zh)
*
|
2021-03-30 |
2023-02-01 |
英商康派斯開拓者公司 |
賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法
|
|
CA3215871A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Lyfe Chng, Llc |
Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
|
|
US20220331292A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Callitas Health Inc. |
Compositions and methods for delivery of psilocin and prodrugs thereof
|
|
WO2022221942A1
(en)
*
|
2021-04-19 |
2022-10-27 |
Betterlife Pharma Inc. |
Prevention of drug diversion
|
|
EP4329759A4
(en)
|
2021-04-30 |
2025-07-16 |
Mind Medicine Inc |
CRYSTALLINE FORMS OF LSD SALTS
|
|
JP2024517194A
(ja)
*
|
2021-05-03 |
2024-04-19 |
マインド メディシン， インコーポレイテッド |
サイケデリック薬の用量を漸増する方法
|
|
WO2022235514A1
(en)
*
|
2021-05-04 |
2022-11-10 |
Mind Medicine, Inc. |
Liposome delivery of psychedelics
|
|
WO2022261058A1
(en)
*
|
2021-06-07 |
2022-12-15 |
University Of Mississippi |
Methods for the pulsed delivery of bioactive agents
|
|
US11801256B2
(en)
|
2021-06-08 |
2023-10-31 |
Universitätsspital Basel |
Antidepressant-psilocybin co-treatment to assist psychotherapy
|
|
GB202109023D0
(en)
*
|
2021-06-23 |
2021-08-04 |
Ldn Pharma Ltd |
Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3
|
|
WO2022272176A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Synaptive Therapeutics, Llc |
Psilocybin analogs for treating psychological disorders
|
|
JP7846211B2
(ja)
|
2021-08-19 |
2026-04-14 |
デフィニウム セラピューティクス ユーエス， インコーポレイテッド |
治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
|
|
US12492178B2
(en)
|
2021-09-01 |
2025-12-09 |
Empathbio, Inc. |
Stable polymorph of R-MDMA HCl
|
|
EP4396162A4
(en)
*
|
2021-09-03 |
2025-11-12 |
Alexander Shulgin Res Institute Inc |
ASYMMETRIC ALLYL TRYPTAMINES
|
|
US20230099972A1
(en)
*
|
2021-09-30 |
2023-03-30 |
ATAI Life Sciences AG |
Compositions and methods for treating headaches
|
|
WO2023086962A1
(en)
*
|
2021-11-12 |
2023-05-19 |
Terran Biosciences Inc. |
Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
|
|
US20250011351A1
(en)
|
2021-11-12 |
2025-01-09 |
Terran Biosciences Inc. |
Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
|
|
US11912680B2
(en)
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
|
WO2023129956A2
(en)
|
2021-12-30 |
2023-07-06 |
ATAI Life Sciences AG |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
CN118984868A
(zh)
|
2021-12-31 |
2024-11-19 |
恩派瑞安神经科学公司 |
用于产生精神药物生物碱的遗传修饰的生物体
|
|
EP4463153A4
(en)
*
|
2022-01-12 |
2026-03-04 |
Eleusis Therapeutics Us Inc |
Psilocin benzoate formulation for intravenous infusion
|
|
WO2023168023A1
(en)
|
2022-03-04 |
2023-09-07 |
Reset Pharmaceuticals, Inc. |
Co-crystals or salts comprising psilocin
|
|
WO2023183618A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Ojai Energetics Pbc |
Psychedelic compositions and methods for forming the same
|
|
EP4514831A1
(en)
*
|
2022-04-27 |
2025-03-05 |
Howard Hughes Medical Institute |
Chemogenetic receptors and methods of making and using
|
|
US20250114383A1
(en)
*
|
2022-05-13 |
2025-04-10 |
Reset Pharmaceuticals, Inc. |
Administration of a psychedelic compound by intravenous infusion
|
|
IL315086A
(en)
|
2022-06-09 |
2024-10-01 |
Diamond Therapeutics Inc |
Amorphous (A-polymorphic) psilocybin
|
|
WO2023248222A1
(en)
*
|
2022-06-21 |
2023-12-28 |
Technion Research & Development Foundation Limited |
5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders
|
|
US20240000795A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Terran Biosciences Inc. |
Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
|
|
WO2024015447A1
(en)
*
|
2022-07-12 |
2024-01-18 |
Lobe Sciences Ltd. |
Preparation of stable psilocin salts, esters and conjugates and uses thereof
|
|
US12344583B2
(en)
|
2022-07-12 |
2025-07-01 |
Lobe Sciences Ltd. |
Solid psilocin salts
|
|
WO2024019908A1
(en)
*
|
2022-07-19 |
2024-01-25 |
Lobe Sciences Ltd. |
Serotonergic psychedelic agent for treating selective mutism
|
|
US12264131B2
(en)
|
2022-08-19 |
2025-04-01 |
Beckley Psytech Limited |
Pharmaceutically acceptable salts and compositions thereof
|
|
WO2024079648A1
(en)
*
|
2022-10-11 |
2024-04-18 |
Sintalica S.R.L. |
Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof
|
|
WO2024151625A1
(en)
*
|
2023-01-10 |
2024-07-18 |
Georgetown University |
Non-toxic plga compositions and methods of making and using same
|
|
CN121358470A
(zh)
*
|
2023-02-23 |
2026-01-16 |
布莱特西德公司 |
用于调节g蛋白偶联受体的组合物和方法
|
|
US12246005B2
(en)
|
2023-06-13 |
2025-03-11 |
Beckley Psytech Limited |
5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
|
|
WO2025010308A2
(en)
*
|
2023-07-03 |
2025-01-09 |
Empathbio, Inc. |
Mdma enantiomer compositions and methods for modulating aggression response
|
|
WO2025024400A2
(en)
*
|
2023-07-21 |
2025-01-30 |
2A Biosciences, Inc. |
Substituted tryptamines and uses thereof
|
|
WO2025040932A1
(en)
*
|
2023-08-21 |
2025-02-27 |
Nechama Golan |
Fully curing all mental diseases with the use of d-lysergic acid amide in different doses and time of treatment
|
|
WO2026068690A1
(en)
*
|
2024-09-27 |
2026-04-02 |
Medichem, S.A. |
Quetiapine long-acting injection
|